News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Dunkirk retreat: ImmunityBio, aiming to hire 300 in 30 months, lays off staff at new facility https://www.fiercebiotech.com/biotech/dunkirk-retreat-immunitybio-aiming-hire-300-30-months-lays-staff-new-facility

ImmunityBio: Huge Slump On Small Raise Before Approval Raises Questions https://seekingalpha.com/article/4590378-immunitybio-huge-slump-small-raise-before-approval-raises-questions?mailingid=30974195&messageid=must_reads&serial=30974195.3685050&utm_campaign=Must%2BReads%2Brecurring%2B2023-03-27&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads

Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLC https://www.prnewswire.com/news-releases/court-confirms-sorrento-therapeutics-incs-125-million-arbitration-award-against-nantpharma-llc-301775093.html

https://www.swfinstitute.org/news/96036/taking-on-expensive-debt-nanthealth-announces-22-5-million-new-financing-with-highbridge-and-nant-capital

NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight Read more: https://www.digitaljournal.com/pr/news/nk-cell-therapy-pipeline-analysis-demonstrates-novel-100-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight#ixzz7u2chf4yz

A positive difference in physical function in responders versus non-responders was noted The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 16, 2023-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting “Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG” at the ASCO Genitourinary Cancers Symposium (ASCO GU) conference in San Francisco, February 16-18. The Food and Drug Administration (FDA) is currently reviewing the Biologics License Application (BLA) for ImmunityBio’s N-803 plus BCG for the treatment of NMIBC CIS with a Prescription Drug User Fee Act (PDUFA) date of May 23, 2023. Details about the presentation are below: Date: February 16, 2023 Track: Urothelial Carcinoma, Prostate Cancer-Advanced Sub-Track: Symptoms, Toxicities, Patient-Reported Outcomes and Whole-Person Care Title: Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG Presenter: Dr. Karim Chamie, Associate Professor of Urology at UCLA Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma Abstract #: 495 Location: Poster Board J17 Session Times: 11:30 a.m.-1:00 p.m.; 5:45-6:45 p.m. PST

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-present-quality-life-quilt-3032-study-patients-bcg?field_nir_news_date_value[min]=

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-execution-50-million-equity-financing?field_nir_news_date_value[min]=

The judgments followed Claimants’ filing of petitions in the Superior Court to confirm the arbitration award, and Sorrento’s response to the petitions in the form of a motion to vacate the award, which was denied. In addition to confirming the award, the Superior Court granted Claimants’ request for an injunction against Sorrento to prevent Sorrento from making overseas transfers over $1 million, and certain transfers to company insiders, until the award is paid. The Company intends to continue to pursue vigorously the collection of the judgments and 10% post-judgment interest from Sorrento, but we make no assurances that we will receive the full amount or with respect to the timing of our receipt of the funds. Other previously disclosed disputes (Superior Court actions) between affiliates of the Company and Sorrento remain pending, and the Company and its affiliates intend to continue to vigorously defend any claims asserted against it. https://fintel.io/doc/sec-immunitybio-inc-1326110-8k-2023-february-13-19401-4372

Immunitybio Inc - Financial Statements and Exhibits, Other Events - 8-K - February 13, 2023 On February 7, 2023, the Los Angeles County Superior Court entered orders confirming the previously disclosed arbitration award against Sorrento Therapeutics, Inc. (“Sorrento”) and judgments against Sorrento in the aggregate amount of approximately $176.37 million plus 10% post-judgment interest, of which approximately $159.42 million is payable to NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc. (the “Company”), and the remainder of which is payable to Immunotherapy NANTibody, LLC, a joint venture between the Company and Sorrento (“NANTibody” and together with the Company, “Claimants”). As previously disclosed, on December 2, 2022, the arbitrator had executed a final award finding Sorrento’s breaches of exclusive license agreements with the Claimants, awarding $173.5 million in the aggregate with prejudgment interest running until the date of judgment, and determining that the Claimants are entitled to declaratory relief that both license agreements remain in full force and effect with respect to ImmunityBio’s PD-L1 NK cell. The arbitrator’s award further declared that Sorrento and Claimants have no further rights or obligations under either license agreement with respect to other targets, that Sorrento has no further obligation to contribute materials or know how with respect to the PD-LI antibody, and that Claimants are not required to return any materials or know how received from Sorrento.

Novel Cancer Vaccine Yields Promising Survival Rates in Pancreatic Cancer https://www.targetedonc.com/view/novel-cancer-vaccine-yields-promising-survival-rates-in-pancreatic-cancer

Ich glaube in der Meldung ist ein Schreibfehler, weil es um 157 Millionen Dollar ging, hab den Artikel aber 1:1 übernommen.

Sorrento Can't Nix $175M Arbitration Loss To LA Times Owner A California judge denied Sorrento Therapeutics' request Tuesday to vacate a $175 million arbitration award granted to billionaire Patrick Soon-Shiong's immunotherapy companies https://www.google.com/amp/s/www.law360.com/amp/articles/1573913

Kurze Zusammenfassung der aktuellen Lage: https://youtu.be/-aBb87tNGmY

Experts’ summary: This single-arm trial tested the IL-15 superagonist nogapen- dekin o-inbakicept (NAI, also known as N-803) plus bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC). A complete response (CR) at any time was observed in 71% (95% confidence interval [CI] 59.6-80.3%) of patients with BCG-unresponsive carcinoma in situ (CIS) + Ta/T1 and the med- ian duration of response was 26.6 mo. The disease-free survival (DFS) rate at 12 mo for patients with Ta/T1 tumors without CIS was 55.4% (95% CI 42.0-66.8%). CR was observed in only two of ten patients treated with NAI alone. The results show that the therapy was safe, with a low rate of adverse events [1]. Experts’ comments: This trial sets a new benchmark for 3-6-mo CR and 12-mo durability of response in patients with BCG-unresponsive

Dr. Pat Soon-Shiong @DrPatSoonShiong Experts in the field of #bladder cancer #nmibc, Words of #Wisdom @pcvblack @MariePierStLau1 https://mobile.twitter.com/drpatsoonshiong/status/1622037502797422595?s=12